Based on ~45,0000 completed automated comprehensive biopsychosocial screens and a sub-set of urological cancer patients, clinical and programmatic relevant information will be presented that has the potential to more deeply engage patients and their families. Additional benefits include, higher levels of real-time objective communication among health care providers, enhanced quality of care and reduced costs. Given increasing Randomized Control Trial evidence for the importance of ongoing communications and support for quality and extended length of life, screening is emerging as the 6th Vital Sign internationally. Australian psycho-oncologists have played a significant role in the development of new knowledge in biopsychosocial screening. Based on 26 years of first-hand experience in creating, sustaining and growing such programs, the speaker will briefly share biopsychosocial screening data illuminating specific benefits to patients, families and health care providers across settings. Data will then be shared that is focused on urological cancers and the impact of age, sex, income and the full range of biopsychosocial problems and opportunities. Finally, information will be shared relating to how automated comprehensive screening supports team work, clarifies provider functions, saves physician time, and creates unique actionable data sets for enhancements to clinical care, programmatic development and research.